Regulation - Victoza, Diabetes

Filter

Current filters:

VictozaDiabetes

Popular Filters

Novo Nordisk files for approval of high strength liraglutide for obesity

Novo Nordisk files for approval of high strength liraglutide for obesity

22-12-2013

Danish insulin giant Novo Nordisk has filed separate regulatory submissions with the US Food and Drug…

DiabetesEuropeliraglutideMetabolicsNorth AmericaNovo NordiskPharmaceuticalRegulationVictoza

Novo Nordisk files Tresiba/Victoza combo IDegLira for EU approval

31-05-2013

Danish insulin giant Novo Nordisk (NOV: N) said today (May 31) that it has submitted a marketing authorization…

DiabetesEuropeIDegLiraNovo NordiskPharmaceuticalRegulationTresibaVictoza

Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"

23-11-2012

The recent European Medicine Agency advisory committee, CHMP, positive opinion for French drug major…

BiotechnologyDiabetesFinancialLantusLyxumiaNovo NordiskRegulationResearchSanofiTresibaVictozaZealand Pharma

Positive Ph III results for Novo Nordisk's degludec; US advocacy calls for Victoza's withdrawal

23-04-2012

Danish diabetes specialist Novo Nordisk (NOV: N) says that its investigational ultra-long-acting insulin…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationResearchVictoza

Victoza US label update includes superior efficacy over Januvia, says Novo Nordisk

10-04-2012

The US Food and Drug Administration has approved an update to the product label for Victoza (liraglutide…

DiabetesJanuviaLevemirMerck & CoNorth AmericaNovo NordiskPharmaceuticalRegulationResearchVictoza

EU OKs two new indications for Novo Nordisk’s Levemir

03-11-2011

There was good news for Danish insulin giant Novo Nordisk (NVO: N) yesterday, when the European Commission…

DiabetesEuropeLevemirNovo NordiskPharmaceuticalRegulationVictoza

AstraZeneca to investment $200 million in Chinese manufacturing plant; Novo Nordisk debuts Victoza

10-10-2011

Anglo-Swedish drug major AstraZeneca ILSE: AZN) said this morning that it is investing $200 million in…

Asia-PacificAstraZenecaDiabetesFinancialMarkets & MarketingNovo NordiskPharmaceuticalRegulationVictoza

Back to top